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1. Introduction 
During the last decade, there has been enormous progress in understanding both 
multipotent stem cells such as hematopoietic stem cells and pluripotent stem cells such as 
embryonic stem cells and induced pluripotent stem cells. However, it has been challenging 
to study developmental potentials of these stem cells because they reside in complex cellular 
environments and aspects of their distribution, migration, engraftment, survival, 
proliferation, and differentiation often could not be sufficiently elucidated based on limited 
snapshot images of location or environment or molecular markers (Jang et al., 2011). 
Therefore, reliable imaging methods to monitor or track the fate of the stem cells are highly 
desirable. Both short-term and more permanent monitoring of stem cells in cultures and in 
live organisms have benefited from recently developed imaging approaches that are 
designed to investigate cell behavior and function. Transmission electronic microscopy 
(TEM) and series of noninvasive imaging technologies enable us to investigate cell behavior 
in the context of a live organism. In turn, the knowledge gained has brought our 
understanding of stem cell biology to a new level. 
Cell based therapeutics are emerging as powerful regimens. To better understand the 
migration and proliferation mechanisms of implanted cells, a means to track cells in living 
subjects is essential, and to achieve that, a number of cell labeling techniques have been 
developed. Nanoparticles, with their superior physical properties, have become the 
materials of choice in many investigations along this line. Owing to inherent magnetic, 
optical or acoustic attributes, these nanoparticles can be detected by corresponding imaging 
modalities in living subjects at a high spatial and temporal resolution. These features allow 
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implanted cells to be separated from host cells; and have advantages over traditional 
histological methods, as they permit non-invasive, real-time tracking in vivo (Bhird et al., 
2011).  
Superparamagnetic iron oxide nanoparticles and magnetic resonance imaging provide a 
non-invasive method to detect and label hematopoietic stem cells. These nanoparticles 
exhibit unique properties of superparamagnetism and can be utilized as excellent molecular 
probes for magnetic resonance imaging. Neumaier et al., (2008) related that cell labeling by 
iron oxide nanoparticles has emerged as a potentially powerful tool to monitor trafficking of 
a large number of cells in the cell therapy field. Magnetic resonance imaging and iron 
magnetic nanoparticles are able to increase the accuracy and the specificity of imaging and 
represent new imaging opportunities in preclinical and translational research (Neumaier et 
al., 2008). 
Superparamagnetic behaviour of the marker used (magnetic fluid), composed of iron oxide 
(Fe3O4), comes from particles where the magnetization is free to re-orient itself due to 
thermal fluctuations (Sastry et al. 1995), characterizing the presence of electron-dense 
granules detectable by TEM. As described above, the nanoparticles can also be detected by 
magnetic resonance techniques, both in vitro and in vivo. The fundamental state of the free 
ion (Fe3+) has an electronic configuration of 3d5, having all its 5 spins bound (S=5/2 and 
total momentum orbital=null), giving a 6S configuration for the fundamental state, 6 times 
degenerated, forming 3 pairs of Kramers levels separated by the local electrical field (Stark 
effect). Since Fe3+ is an ion with an odd number of unpaired electrons, the duplet’s 
degeneration can only be possible by a magnetic field and then the electronic paramagnetic 
resonance (EPR) can be observed.  
CD133 antigen is a surface molecule with unknown functions expressed by more primitive 
CD34+ hematopoietic progenitor cells (HPCs) (Miraglia et al., 1997). The presence of antigen 
CD133 on a subset of very primitive HPCs such as CD34/CD133 cells points to this marker 
as an attracting tool to isolated human HPCs for biologic studies and clinical purposes 
(Peichev et al., 2000). 
In humans, CD133 is expressed in stem cells (Yin et al., 1997) and in several cellular 
progenitors (Yin et al., 1997), including those derived from the hematopoietic and nervous 
systems (Yin et al., 1997; Miraglia et al, 1997). CD133 expression is also detected in other 
primitive cells (Gehling et al., 2000) and in some tumors, such as retinoblastoma, 
glioblastoma, and medulloblastoma (Yin et al., 1997; Pfenninger et al., 2007).  
Human cord blood has been described as an excellent source of CD133+ HPCs with a large 
application potential (Rubinstein et al., 1998; Kuci et al., 2003).  
A large number of studies on stem cell biology and HPCs transplantation indicate that 
umbilical cord blood (UCB) is a suitable source of transplantable human HPCs (Gluckman 
et al. 1997; Rocha et al., 2001).  
BONANNO et al. (2004) described the clinical isolation and functional characterization of 
cord blood CD133+ HPCs with high hematopoietic activity and in vitro mesenchymal 
potential (differentiation mesoderm). Thus, the authors suggest that large-scale isolation of 
CD133+ cells from human UCB could represent a primary step to again access to a stem pool 
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useful for therapeutic hematopoietic transplants, stem cell expansion for clinical purposes 
and pre-clinical research on tissue regenerating therapies. 
In 2007, the same group (BONANNO et al.) related another therapeutic use of CD133+ cells 
from human UCB. They suggested the use of these cells as a treatment for myocardium 
ischemia due their potential to differentiate into endothelial and cardiomyocyte-like cells in 
vitro. In vivo studies showed vasculogenic potential of CD133+ cells from UCB in response to 
ischemia in an animal injury model (Finney et al., 2005; Ma et al., 2005). 
CD133+ cells can be isolated in vitro with monoclonal antibody anti-CD133 bound to 
magnetic beads that are composed of superparamagnetic nanoparticles (Miltenyi Biotec) 
and purified by MACS (magnetic activated cell sorting).  
The low levels of toxicity of the magnetic nanoparticles binding to magnetite (Fe3O4) used in 
the process of cellular selection (MACS - Miltenyi Biotec) can also be observed through 
studies that used hematopoetic stem cells obtained by the same selection procedure, in 
transplants of patients with cancer, obtaining satisfactory therapeutic results (Lang et al., 
2003; Richel, et al., 2000). 
This manuscript presents the study of molecular imaging on CD133+ hematopoietic stem 
cells from human umbilical cord blood.   
2. Materials and methods 
2.1 Collection and selection of the CD133+ hematopoetic stem cells from human 
umbilical cord blood (UCB) 
The collection of the umbilical cord blood was obtained in the Obstetric Centre of the Albert 
Einstein Israelita Hospital, São Paulo, Brazil, from pregnancies at term (n=5) with written 
permission from the mother. The collection was performed with sterile equipment through a 
puncture of the umbilical cord vein, at the moment of birth and after the cord was cut. 
Blood bags with a maximum volume of 250mL with 2mL of anticoagulant were used. The 
volume of the collected blood varied between 70 and 120mL. A sample of 80µL of blood was 
separated for cell count. The blood was then diluted in 1:2 proportion in a RPMI (Gibco) 
culture medium and the limpho-mononuclear cells were separated by the Ficoll-PaqueTM 
Plus (Amersham – GE Healthcare) density gradient in a 1:3 proportion (Lehner & Holter, 
2002). After 35 minutes in a 400g centrifuge, the fraction of the limpho-mononuclear cells 
were carefully isolated with the help of a 10mL pipette and washed in RPMI.  
The CD133+ cell population was purified following the separation protocol by MiniMACS 
microbeads affinity chromatography using anti-CD133 bound to magnetic beads (Miltenyi 
Biotec). 
The cells were filtrated in 30µm nylon filters and the number of these cells were determined 
by the cell count in an automatic counter (Coulter), after which they were centrifuged (400g 
for 5 minutes) and resuspended in the proportion of 300µL of solution for each 108 cells in a 
PBS solution containing 2mM EDTA and 0.5% BSA (solution 1). For each 108 cells, 100µL of 
FcR blocker and 100µL of magnetic micro-spheres with CD133+ antibodies (6°C) were 
added. The labelled cells were centrifuged and resuspended in solution 1 to be separated in 
the chromatography column to isolate only the CD133+ cells.   
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2.2 Flow cytometry 
After CD133+ cell separation, the cell population was characterized by flow cytometry using 
the following monoclonal antibodies (Becton Dickinson, San Jose, CA) and (Miltenyi Biotec): 
CD34 (clone: 581) FITC-conjugated, CD45 (clone: 2D1) PerCP Cy-5.5-conjugated and 
CD133/2 (clone: AC141) APC-conjugated and the respective isotype controls IgG1 FITC-
conjugated, IgG1 PerCP Cy-5.5-conjugated and IgG1 APC-conjugated. 
Cells were incubated with antibodies at 4oC, on dark for 30 minutes, and then washed with 
PBS and fixed with 1% paraformaldehyde. A total of 105 fluorescent cellular events were 
acquired on the FACSARIA flow cytometry (BD Bioscience) and analyzed by FACSDIVA 
software. Briefly, the analysis was performed by gating the cell population on forward 
scatter (FSC) versus side scatter (SSC) followed by gating only the CD45+ cells. Within the 
CD45+ cell population, cells were analyzed for expression of CD34 and CD133 markers.   
2.3 Transmission Electron Microscopy (TEM) 
CD133+ cell population (107 cells) was fixed in 0,5% glutaraldehyde in 0,2M cacodylate 
buffer for two hours at 4°C. Two 15 minute washes in cacodylate buffer followed this 
process. Post-fixation was performed in 1% osmium tetroxide for one hour at 4°C, followed 
by another two 15 minute washes in the same buffer. For contrast, the material was 
immersed in a solution of uranyl acetate in acetone for 30 minutes. After dehydration, the 
material was embedded in Epon resin diluted in acetone (1:1) and incubated at 4°C with 
agitation for 24 hours. The material was then transferred to pure Epon resin and incubated 
at 60° C for 72 hours, until completely polymerized. Semi and ultrathin sections were 
obtained with the aid of a Porter Blum ultramicrotome. The semithin sections were stained 
with azur II (1%) and methylene blue (1%). The ultrathin sections were placed on copper 
grids and stained with uranyl acetate and lead citrate. The grids were studied and 
photographed in a transmission electron microscope, PHILLIPS CM100. 
2.4 Electron Paramagnetic Resonance (EPR) 
In order to corroborate with the referred marking of the CD133+ cells bound to iron oxide 
superparamagnetic nanoparticles the EPR technique was used. 
The EPR signal of the iron oxide nanoparticles (iron markers Fe3O4) describe a peculiar 
absorption curve of approximately g= 2,0 where the curve area (double integral of the EPR 
spectrum) is proportional to the concentration of the sample nanoparticles. 
To perform a quantitative analysis of the Fe3O4 concentration, a calibration curve was first 
built based on different known concentrations between 2,6µm and 0,6mM. 
The sample preparation was obtained from a suspension of 107 stem cells (CD133+), bound 
to iron oxide nanoparticles, in 0,5% glutaraldehyde fixative in a 2µL quartz tube. Following 
this, the EPR measurements were performed. The methodology of the quantification 
calibration was already described in previous studies Gamarra et al. (2007); Sadeghiani et 
al., (2005); Lacava et al., (2002). 
The EPR measurements were taken using 20.166mW power, 1,6x105 receiver gain, 4 
scanning and the measurements were taken at room temperature. The spectral composition 
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of EPR absorption was obtained with a Bruker homodyne spectrophotometer, model EMX, 
operating with a frequency of 9,2 GHz in the band X and modulated to 100 kHz, utilizing 
one cavity of a rectangular microwave in the operating mode of the dominant cavity TE102.  
3. Results  
3.1 Characterization by flow cytometry of CD133+ stem cells from UCB  
After selection of CD133+ cells with monoclonal antibodies bound to superparamagnetic 
nanoparticles, flow cytometry analysis revealed that about 82% of the population is 
comprised by CD34+/CD133+ cells, most of them expressing CD133 (Figure 1). After this 
first analysis, the ultrastructural characterization of the CD133+ cells was performed. 
 
Fig. 1. (A) The Flow Cytometry graph shows that CD133+/CD34+ (82,0%), CD133/CD34+ 
(1,6%) and CD34+CD133- (9,2%). (B) Isotype control graph shows that wasn’t unspecific 
staining.   
3.2 Identification and ultrastructural characterization of CD133+ stem cells labelled 
with nanoparticles 
Under the electron microscopy, ultrastructural analysis highlighted the presence of 
electrondense granules in the cell surface. This demonstrates the presence of anti-CD133 
monoclonal antibodies bound to superparamagnetic nanoparticles recognizing the CD133 
membrane protein (Figures 2A, B, C, D). This does not occur in the cells of the control group 
(CD133-) (Figures 3C, D) since similar electrondense signal surrounding cellular membrane 
of CD133- cells (control group) were not detected (Figures 3C, D).  
Electrondense signals related to superparamagnetic nanoparticles were also observed in the 
cell cytoplasm, suggesting their internalization through the process of the endocytosis 
(pinocytosis) of nanoparticles bound to the antibodies (Figures 2C, D; 3A, B). CD133+ cells 
incorporated superparamagnetic nanoparticles through its small cytoplasmic projections 
forming the pinocytics vesicles, as shown in the figures 2C and 3B.  
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Fig. 2. Transmission electronic microscopy of CD133+ stem cells. n = nucleus, c = cytoplasm, 
arrow = electrondense granules or magnetic nanoparticles, pv = pinocytics vesicles. Scale: 
A) 1µm; B) 0,5µm; C) 0,25µm; D) 0,125 µm.  
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Fig. 3. (A, B) Transmission electronic microscopy of CD133+ stem cells. (C, D) Transmission 
electronic microscopy of CD133- stem cells (control). n = nucleus, mi = mitochondria, mt = 
microtubules, arrow A = electrondense granules or magnetic nanoparticles, arrow B = 
absence of the electrondense granules or magnetic nanoparticles, pv = pinocytics vesicles, li 
= lipids, v = vacuoles. Scale: A) 1µm; B) 0,5µm; C) 0,25µm; D) 0,25µm.  
3.3 Electron Paramagnetic Resonance (EPR) of the superparamagnetic nanoparticles 
labelled of CD133+ stem cells 
To clearly show the expression of CD133 antigenic marker of the cell population under 
study, an EPR spectrum was first performed only with monoclonal antibodies anti-CD133 
bound to magnetic nanoparticles composed of superparamagnetic nanoparticles. A 
resonance in g=2.0 (Figure 4) was observed, derived from Fe3+ spins that interact with 
themselves, but with a supermagnetic behavior that characterizes the presence of 
agglomerates (Gamarra et al., 2005; Hseih et al., 2002; Sharma & Waldner, 1977). This signal 
consists of a strong absorption, while the large width is attributed to the strong interaction 
between Fe3+ ions (Fe3+ ion cluster agglomerated by a strong exchange interaction). 
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Fig. 4. EPR spectra, showing the resonance absorption curve of the superparamagnetic 
nanoparticles, labelled cells (CD133+), unlabelled cells (CD133-) and glutaraldehyde 0,5% 
fixative. The spectra are shown in the inset.  
EPR spectrum of the labelled cells (CD133+) was then performed, observing a resonance line 
in g=2.0 showing the presence of the magnetic nanoparticles bound to the cells, which were 
immersed in glutaraldehyde 0,5% fixative. This fixative was removed by centrifugation of 
the labelled cells and it was analyzed using the EPR spectrum. This spectrum showed the 
absence of resonance in glutaraldehyde fixative thus evidencing the absence of iron oxide 
superparamagnetic nanoparticles in the fixative. 
As expected, the EPR spectrum of unlabelled cells (CD133-), used as negative controls, did 
not present a resonance line.  
4. Discussion  
Modern imaging technologies that allow for in vivo monitoring of cells in intact research 
subjects have opened up broad new areas of investigation. In the field of hematopoiesis and 
stem cell research, studies of cell trafficking involved in injury repair and hematopoietic 
engraftment have made great progress using these new tools. Multiple imaging modalities 
are available, each with its own advantages and disadvantages, depending on the specific 
application. For mouse models, clinically validated technologies such as magnetic resonance 
imaging (MRI) and positron emission tomography (PET) have been joined by optical 
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imaging techniques such as in vivo bioluminescence imaging (BLI) and fluorescence 
imaging, and all have been used to monitor bone marrow and stem cells after 
transplantation into mice. Each modality requires that the cells of interest be marked with a 
distinct label that makes them uniquely visible using that technology. For each modality, 
there are several labels to choose from. Finally, multiple methods for applying these 
different labels are available (Duda et al., 2007). 
In this work was described the molecular imaging on CD133+ hematopoietic stem cells from 
human umbilical cord blood through the nanobiotechnological applications. We were able to 
distinguish CD133+ from CD133- cells by TEM, based on their attachment to nanoparticles, as 
well as by signal analysis of EPR generated by these nanoparticles. Our findings indicate 
potential nanobiotechnological applications for in vivo cell imaging and therapy. 
In the hematopoietic system, CD133 is especially expressed in stem cells and progenitor cells 
found in the bone marrow, peripheral blood and human umbilical cord blood, which was 
used as the cellular source for this study (Yin et al., 1997; Miraglia et al. (1997). Recent data 
suggest that CD133+ cells, besides having extensive hematopoietic plasticity (Wynter et al., 
1998), can be used in different clinical applications, being an alternative in the utilization of 
CD34+ cells, more commonly used in transplant protocols (Handgretinger et al., 2003). 
CD133+ cellular fraction of bone marrow harbors precursors of granulocytes/macrophages 
and dendritic cells (Yin et al., 1997). 
Studies performed by Gehling et al. (2000) demonstrated that CD133+ cells have the capacity 
to differentiate in endothelial cells. After that, other researchers identified an endothelial 
progenitor (CD133+) that co-expresses the receptor for vascular endothelial growth factor 
(VEGFR) (Gill et al., 2001). They also detected functional responses in these cells during 
vascular trauma, suggesting that these CD133+ endothelial progenitors can be mobilized by 
VEFG, being useful in repairing vascular tissue injury (Gill et al., 2001). 
Powell et al. (2005) related diseases of the coronary arteries with the reduction of fractions 
from three different sub-types of CD133+ circulant cells: CD133+CD34+; CD133+CXCR4+ and 
CD133+VEGFR2+. These data indicated that the functional meaning of CD133 positive 
cellular fractions (CD133+) transcends the hematopoietic tissue (Bhatia, 2001). 
In the present study, after the previous analysis of flow cytometry confirming the significant 
expression (82%) of the CD133 cell surface antigen (CD133+ phenotype) in the stem cells of 
the human umbilical cord blood (UCB), the analysis of these cells through Transmission 
Electronic Microscopy (TEM) was performed.  
The electron micrographs highlighted the presence of electrondense granules in the cellular 
membrane, as well as dispersed in the cytoplasm of CD133+ cells, which refers to the 
superparamagnetic nanoparticles bound to anti-CD133 monoclonal antibody. These 
electronic micrographs described an important ultrastructural finding related to the 
presence of vesicles that internalize of nanonoparticles conjugated to anti-CD133 by the 
process of pinocytosis for all antibodies tested. We suggest that in our study the pynocytisis 
occur by receptor-mediated endocytosis. The endocytosis process happens after the 
antibody biding to the receptor, and then a depression arises on the cell membrane which is 
followed by the formation of the pinocytic vesicles. These pinocytic vesicles that are 
surrounded by the cytoplasmic proteins called clatrines, are internalized (Pavon et al., 2010). 
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Electron Paramagnetic Resonance (EPR) analysis of the CD133+ stem cells from UCB 
detected that the signal (spectrum) generated by the labelled cells comes from the 
superparamagnetic nanoparticles composed of iron oxide bound to these cells. 
For spectrum detection of the EPR of the superparamagnetic nanoparticles it was necessary 
to perform an earlier study of the qualitative visualization through TEM of these 
nanoparticles also bound to CD133+ stem cells. The micrographies showed that the anti-
CD133 antibodies, bound to nanoparticles are bound to the cell surface antigens, thus 
demonstrating that the stem cell morphology, even after the selection process, was 
preserved. In this way the information of the analysis of the quantification by EPR of the 
iron content in the cells was validated (Billotey et al., 2003; Wilhelm et al., 2002), which is 
necessary for the intensity study of the image signal by magnetic resonance (MRI), to obtain 
the molecular image. 
This findings may guide future research in the study of molecular imaging on CD133+ 
haematopoietic stem cells from human umbilical cord blood, highlighting the 
immunolocalization of monoclonal antibodies associated with superparamagnetic 
nanoparticles, as well as the signal detection generated by these nanoparticles (EPR) bound 
to the cells studied, suggest many biomedical applications using new resources in 
nanoscience as they become available. The EPR results, together with ultrastructural 
characterization of immunolocalized nanoparticles, strongly suggest that CD133+ cells 
labelled with nanoparticles can be considered for different nanobiotechnological 
applications, i.e., matter manipulation in a nanometric scale to help areas such as diagnosis, 
therapeutics or even bioengineering (Fargeas et al., 2006). This is because these CD133+ cells 
from human UCB could represent a primary step to again access to a stem pool useful for 
therapeutic hematopoietic transplants, stem cell expansion for clinical purposes and pre-
clinical research on tissue regenerating therapies. 
Recent developments are revolutionizing the understanding about hematopoietic stem-cell 
therapy. Over the past three decades, much knowledge has been accumulated to provide a 
sound basis for the optimal use of this approach in the treatment of hematopoietic cancers, 
especially acute myelogenous leukemia, Hodgkin's disease and other lymphomas and 
multiple myeloma (Verlinden et al., 1998; Thomas; Chift, 1999; Negrin et al., 2000; Childs et 
al., 2000; Sharp et al., 2000). This approach has also been used in the treatment of some solid 
tumors, most notably breast cancer, for which its value is still in dispute because of poor 
accrual in randomized trials and because it takes many years to obtain definitive answers, 
even from well-designed trials (Joshi et al., 2000). Hematopoietic stem-cell therapy is also 
being tried in sickle cell disease and thalassemia and recently in progressive multiple 
sclerosis, systemic scleroderma, severe systemic lupus erythematosus, and rheumatoid 
arthritis with a poor prognosis (Shichishima et al., 1983; Papanikolaou et al., 2011; 
Alderucciro et al., 2011). 
The broadening therapeutic applications of hematopoietic stem cells also reflect an 
increased understanding of how to modulate the cells of the immune system to minimize 
both rejection and graft-versus-host disease and to improve the management of the 
infectious complications of immunosuppression (Verlinden et al., 1998; Sharp et al., 2000). 
While much has been studied about hematopoietic stem-cell therapy several questions 
remain regarding the biology of stem cells in living subjects. For most therapeutic 
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applications of regenerative medicine, critical issues such as stem cell type and delivery 
route of stem cells remain to be elucidated. In addition, after cells are transplanted to the 
living subject, it becomes critical to understand the biology of transplanted cells and how 
they interact with the microenvironment. Recent developments in molecular imaging 
modalities may likely permit investigators to answer some of these questions. Furthermore, 
some of these imaging strategies have the potential to be translated to patients, which makes 
them plausible to be used in the clinics.  
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